Modern healthcare is moving away from one-size-fits-all treatment. Diatech Pharmacogenetics envisions a future where precision medicine is not a privilege, and genomic testing is an essential and accessible part of healthcare. Oliva Alberti, CEO of Diatech Pharmacogenetics, tells Nxtin.Health how science is pushing the boundaries of personalised medicine.
Pathology departments and molecular laboratories in more than 50 countries use your solutions. For readers outside the lab, how would you describe Diatech’s role between a patient’s sample and the treatment decision their doctor makes? And when you talk to laboratories around the world, what are they asking for that today’s tools can’t yet give them? How does that guide where you invest in R&D?
The products—or, more precisely, the reagents—that we manufacture fit into the workflow following a cancer diagnosis and the associated surgery (where required) or blood draw. DNA and RNA are extracted from the patient’s diseased tissue and analyzed using our solutions which identify molecular alterations. These alterations will be taken into consideration for a personalized treatment approach.

As for the second part of your question, it is fair to say that significant progress has been made in terms of instrumentation; innovation in this sector has been remarkably rapid. Despite an increase in the number of diagnoses, when caught early, diseases are now treated much more effectively than they were even five years ago. Our investments are in fact based on the guidelines issued by professional associations in this case such as ASCO or ESMO which we try to embrace and use to update our products. In short, as science advances, we adapt accordingly.
Your mission speaks about breaking down barriers to molecular testing, and through your work with laboratories and healthcare institutions in many markets, you see those barriers up close. Where are they highest today? Is it the cost of the test, reimbursement, lab capacity, or doctors who get a genetic result and aren’t sure what to do with it? And which of these is Diatech in a position to change?
The process begins with diagnosis, followed by surgery and sample analysis. Before a sample can be analyzed, it must be prepared and fixed in formalin; the duration of this fixation phase can be critical—if it lasts too long, it may compromise the ability to obtain a complete reading. Another factor that complicates interpretation is a scarcity of sample material—for instance, when a tumor is deeply infiltrative or difficult to access. Beyond this stage, challenges may arise in interpreting genetic data, whether due to a lack of experience or the use of less-than-advanced tools. As you can see, numerous obstacles can emerge at these various points.
Furthermore, given the immense technological and interpretive progress made over the last decade, the training of personnel is not always straightforward—an area where our customer service team provides extensive support to healthcare professionals. Additionally, the rising number of oncological diagnoses has led to an increase in the volume of test reports. Reimbursement for these analyses varies from country to country, depending on the investments made by national healthcare systems, though in some nations, the private sector also plays a significant role, this is another potential barrier to molecular testing adoption.
If we visited your facility in Jesi five years from now, what would we find there that doesn’t exist today? And which of your areas of work do you expect to drive the company’s growth?
Science will guide us toward treatments that are ever more personalized and effective. To keep pace with this trend, over the next five years, we will adapt by implementing diagnostic processes that are increasingly digitized and automated—carried out by machinery, interpreted by software, and validated by human experts. Furthermore, biological samples will likely become easier to analyze. We are therefore moving in this direction.
Your vision is “the right drug, for the right patient, at the right time.” Of those three, which is the hardest to deliver in Europe today?
Timing is certainly fundamental in oncology and given the different specialist areas that the patient passes through, time is certainly the most important challenge.
As President of the Human AI Foundation, you champion “Human AI Teaming,” with people and AI working side by side. In a molecular diagnostics lab, where should the line sit between what an algorithm decides and what a pathologist or geneticist decides? When the AI flags a variant and the specialist disagrees, whose judgement should win? And who is responsible if it turns out to be wrong?
This is a difficult but very interesting question; it is entirely appropriate to raise such concerns. Let us begin with our own field, molecular biology: in its early days, tissues were stained with reagents and examined under a microscope, with interpretation relying on the pathologist’s experience and their personal perception of colors and reactions. As we have seen, we have come a long way since then.
Many tools have been developed to support people in making diagnoses and clinical decisions. Furthermore, our diagnostic tests incorporate internal (endogenous) controls to verify the validity of each test. Regarding AI, the revolution is already underway and, as its use has spread throughout the world, it is in the hands of people both knowledgeable and not. While it certainly serves as a valuable form of support, the expertise of a human professional remains critical. The future of AI in medical diagnostics points toward “augmented,” predictive, and personalized medicine, where algorithms act as tools to provide rapid and precise support to physicians—without replacing human judgment or the doctor-patient relationship.
According to European Union estimates, the adoption of AI-based diagnostic tools is expected to reach nearly 80% of healthcare facilities by 2029. Ultimately, the decision remains a human one. In Italy and across Europe, AI is classified as a support system; the responsibility for diagnosis and treatment always rests with the physician.
Your vision describes a future where precision medicine is a shared reality rather than a privilege. How close do you think Europe is to that today? Which developments make you most optimistic, whether in technology, AI, data or health policy? And what would help genomic testing reach every patient who could benefit from it?
Following our expansion beyond Italy around 2017, Diatech adopted a strategy centered on the democratization of access to precision medicine testing. We have developed user-friendly systems with simplified analysis tools, designed to be effective for everyone—from those just starting out to highly experienced professionals—and suitable for settings ranging from small, routine laboratories to large medical centers. We have even assisted clients in establishing small-scale laboratories in remote, underserved rural areas.
Naturally, the concept of simplifying the analysis workflow has been our guiding principle in design. Europe has reached a high standard of testing, which is now widely implemented across much of the continent; expertise is evolving, driven both by better training and a generational shift. We also recognize that there is still a lot to discover about DNA.
Every day, we analyze billions/millions of genetic data points worldwide—data that often ends up in the cloud, sometimes used for drug development or research, and other times not utilized at all. Diatech, since the beginning, has chosen to let its customers store the data produced within the laboratory or hospital, rather than migrating to an external, unknown cloud environment. We believe that DNA is a highly sensitive and significant type of data, holding immense potential for scientific study and, consequently, substantial economic value. We look to the European Union to provide guidance on this matter.
Consolidating such data into a unified EU cloud could unlock vast opportunities for treatment, research, and development for the scientific community, ultimately for the benefit of all.
Some member states are already implementing this at a national level. Imagine the potential of this repository of genetic data—which connects all Europeans—and what an incredible tool it could be for improving the health of our citizens. It is essential that European policymakers come together to address such issues; scientific progress is constantly evolving, and it must be guided by clear regulations that can safeguard our interests.






